Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD
Baricitinib 4 mg met the primary endpoint in a phase 3 study involving patients with AD who had failed or could not take cyclosporine.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 11, 2022 Category: Internal Medicine Tags: Dermatology News Source Type: news

Management of Atopic Dermatitis: Bringing Therapy Into Focus Management of Atopic Dermatitis: Bringing Therapy Into Focus
Saakshi Khattri, MD, recounts the evolution of treatments for atopic dermatitis (AD), from the widespread use of general immune suppressants such as methotrexate and cyclosporine, to more recent, targeted agents.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 29, 2022 Category: Allergy & Immunology Tags: Dermatology MDAngle Source Type: news

Sandimmune (Cyclosporine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Generic Version of Restasis for Dry Eye FDA Approves First Generic Version of Restasis for Dry Eye
The brand name medicated eyedrops have been available in the United States for nearly 20 years.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Sun Pharma launches dry eye treatment product in Canada
The product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration, Sun Pharma said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news

NLM Technical Bulletin, Nov-Dec 2021, RxNorm November 2021 Release
The RxNorm November monthly release became available for download on Monday, November 1, 2021, and contains a new concept for Restasis single-use vials (RXCUI 2572293).   (Source: NLM Technical Bulletin)
Source: NLM Technical Bulletin - November 1, 2021 Category: Databases & Libraries Source Type: news

FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis
EMERYVILLE, Calif.--(BUSINESS WIRE) June 24, 2021 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2021 Category: Drugs & Pharmacology Source Type: news

Study identifies possible COVID-19 drugs -- including several that are FDA-approved
(University of Pennsylvania School of Medicine) Of the nine drugs found to reduce SARS-CoV-2 replication in respiratory cells, three already have FDA approval: the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 2, 2021 Category: Infectious Diseases Source Type: news

Sandimmune (cyclosporine)
Title: Sandimmune (cyclosporine)Category: MedicationsCreated: 3/12/2021 12:00:00 AMLast Editorial Review: 3/12/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 12, 2021 Category: Rheumatology Source Type: news

Inhaled immunosuppressant may increase survival, pulmonary function after lung transplant
(University of Maryland Medical Center) University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by inhaling a liposomal form of the immunosuppression drug cyclosporine through an investigational nebulizer. This is the first randomized, controlled study to demonstrate increased survival and improved lung function with this drug-device combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2019 Category: International Medicine & Public Health Source Type: news

The Impact of NFAT Inhibition on Neutrophil Antifungal Defense and Myelopoiesis in Cyclosporine A Treated and NFATc1LysM Mice
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Rituximab Noninferior to Cyclosporine in Membranous Nephropathy
WEDNESDAY, July 17, 2019 -- In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in maintaining... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2019 Category: Pharmaceuticals Source Type: news

MENTOR: Rituximab Is a Winner in Membranous Nephropathy MENTOR: Rituximab Is a Winner in Membranous Nephropathy
The anti-CD20 antibody is clearly superior to cyclosporine in inducing, maintaining proteinuria remission in patients with membranous nephropathy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news

Medical News Today: What to know about cyclosporine
This article looks at its uses, dosage, side effects, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

Cyclosporine benefits patients through more rapid remission of proteinuria in lupus nephritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest maintenance therapy with cyclosporine (CYA) results in more rapid remission of proteinuria compared to mycophenolate mofetil (MMF) or azathioprine (AZA) in patients with lupus nephritis. The efficacy of CYA, MMF and AZA in obtaining and maintaining remission of lupus nephritis (LN) is comparable over the long term. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news